Literature DB >> 32609652

Fibromyalgia 2016 criteria and assessments: comprehensive validation in a Norwegian population.

Egil A Fors1, Knut-Arne Wensaas2, Hilde Eide3, Ellen A Jaatun4,5, Daniel J Clauw6,7, Fred Wolfe8,9, Anne-Sofie Helvik10.   

Abstract

Background and aims The ACR1990 criteria of fibromyalgia (FM) have been criticized due to poor reliability of tender points counting (TPC), inconsistent definitions of the widespread pain, and by not considering other symptoms than pain in the FM phenotype. Therefore, several newer self-report measures for FM criteria have emerged. The aim of this study was to translate the fibromyalgia survey questionnaire (FSQ) to Norwegian and validate both the 2011 and the 2016 fibromyalgia survey diagnostic criteria (FSDC) against the ACR1990 criteria. Methods One hundred and twenty chronic pain patients formerly diagnosed with fibromyalgia according to the ACR1990 criteria, and 62 controls not diagnosed or where fibromyalgia was not suspected, were enrolled in this study. All responded to a Norwegian version of the FSQ. Also, they had a clinical examination according to ACR1990 fibromyalgia criteria including a counting of significant tender points with an algometer (TPC). The FSQ with the Widespread Pain Index (WPI) and Symptom Severity scale (SSS) subscales, Fibromyalgia Severity (FS) sum score, was examined for correlations with the fibromyalgia impact questionnaire (FIQ) and TPCs. Face-validity, internal consistence, test-retest reliability and construct validity with convergent and divergent approaches were examined and a Receiver Operating Characteristics (ROC) analysis was performed. Results The internal consistency of FS measured by Cronbach's alfa was good (=0.904). The test-retest reliability measures using intra class correlation were respectable for the FS, including WPI and SSS subscales (0.86, 0.84 and 0.87). FS, WPI and SSS correlated significantly with FIQ (0.74, 0.59 and 0.85) and TPC indicating an adequate construct, convergent validity. The medians of FS, WPI and SSS in the fibromyalgia-group were significantly different from the non-fibromyalgia-group indicating good construct, divergent validity. Using the 2011 and 2016 FSDC vs. ACR 1990 as a reference, sensitivity, specificity, positive likelihood ratio (LR +) and negative likelihood ratio (LR-) were identified. The accuracy rate for both 2011 and 2016 FSDC were respectable (84%). ROC analysis using FS revealed a very good Area Under the Curve (AUC) = 0.860. Conclusion The current study revealed that the Norwegian versions of FSQ is a valid tool for assessment of fibromyalgia according to the 2011 and 2016 (FSDC).

Entities:  

Keywords:  2016 survey and diagnostic criteria; Norwegian; fibromyalgia; questionnaire; validity

Year:  2020        PMID: 32609652     DOI: 10.1515/sjpain-2020-0002

Source DB:  PubMed          Journal:  Scand J Pain        ISSN: 1877-8860


  4 in total

1.  Trajectories of change in symptom severity in patients with fibromyalgia: exploratory analyses of a randomised controlled trial.

Authors:  Trond Haugmark; Kåre Birger Hagen; Sella Aarrestad Provan; Joseph Sexton; Heidi A Zangi
Journal:  Rheumatol Int       Date:  2021-02-15       Impact factor: 2.631

2.  Pre- and post-operative psychological interventions to prevent pain and fatigue after breast cancer surgery (PREVENT): Protocol for a randomized controlled trial.

Authors:  Silje Endresen Reme; Alice Munk; Marianne Therese Smogeli Holter; Ragnhild S Falk; Henrik Børsting Jacobsen
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

3.  Pain Intensity and Sensory Perception of Tender Points in Female Patients with Fibromyalgia: A Pilot Study.

Authors:  Edurne Úbeda-D'Ocasar; Juan Antonio Valera-Calero; Juan Pablo Hervás-Pérez; Mario Caballero-Corella; Cristina Ojedo-Martín; Gracia María Gallego-Sendarrubias
Journal:  Int J Environ Res Public Health       Date:  2021-02-04       Impact factor: 3.390

4.  Development and external validation of a prediction model for patient-relevant outcomes in patients with chronic widespread pain and fibromyalgia.

Authors:  V P Moen; A T Tveter; R D Herbert; K B Hagen
Journal:  Eur J Pain       Date:  2022-03-15       Impact factor: 3.651

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.